A Glycolipid α-GalCer Derivative, 7DW8-5 As a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2022 Jun 24

PMID 35746644

Authors

Huapeng Feng

Ruolin Sun

Guanru Song

Shunfan Zhu

Zhenyu Nie

Liming Lin

Ruonan Yi

Shixiang Wu

Genzhu Wang

Yulong He

Siquan Wang

Pei Wang

Li Wu

Jianhong Shu

Affiliations

Soon will be listed here.

Abstract

Influenza virus infects the host and transmits through the respiratory tract (i.e., the mouth and nose); therefore, the development of intranasal influenza vaccines that mimic the natural infection, coupled with an efficient mucosal adjuvant, is an attractive alternative to current parenteral vaccines. However, with the withdrawal of cholera toxin and Escherichia coli heat-labile endotoxin from clinical use due to side effects, there are no approved adjuvants for intranasal vaccines. Therefore, safe and effective mucosal adjuvants are urgently needed. Previously, we reported that one derivative of α-Galactosylceramide (α-GalCer), 7DW8-5, could enhance the protective efficacy of split influenza vaccine by injection administration. However, the mucosal adjuvanticity of 7DW8-5 is still unclear. In this study, we found that 7DW8-5 promotes the production of secret IgA antibodies and IgG antibodies and enhances the protective efficacy of the split influenza vaccine by intranasal administration. Furthermore, co-administration of 7DW8-5 with the split influenza vaccine significantly reduces the virus shedding in the upper and lower respiratory tract after lethal challenge. Our results demonstrate that 7DW8-5 is a novel mucosal adjuvant for the split influenza vaccine.

Citing Articles

Can invariant Natural Killer T cells drive B cell fate? a look at the humoral response.

Palacios P, Santibanez A, Aguirre-Munoz F, Gutierrez-Vera C, Nino de Zepeda-Carrizo V, Gongora-Pimentel M Front Immunol. 2025; 16:1505883.

PMID: 40040714 PMC: 11876049. DOI: 10.3389/fimmu.2025.1505883.

Local and systemic immune responses induced by intranasal immunization with biomineralized foot-and-mouth disease virus-like particles.

Li S, Zhao R, Song H, Pan S, Zhang Y, Dong H Front Microbiol. 2023; 14:1112641.

PMID: 36819011 PMC: 9937024. DOI: 10.3389/fmicb.2023.1112641.

Sex-Specific Differences in Cytokine Induction by the Glycolipid Adjuvant 7DW8-5 in Mice.

Watson F, Duncombe C, Kalata A, Conrad E, Chakravarty S, Sim B Biomolecules. 2023; 13(1).

PMID: 36671393 PMC: 9855660. DOI: 10.3390/biom13010008.

Development of Nasal Vaccines and the Associated Challenges.

Nian X, Zhang J, Huang S, Duan K, Li X, Yang X Pharmaceutics. 2022; 14(10).

PMID: 36297419 PMC: 9609876. DOI: 10.3390/pharmaceutics14101983.

References

van Riet E, Ainai A, Suzuki T, Hasegawa H . Mucosal IgA responses in influenza virus infections; thoughts for vaccine design. Vaccine. 2012; 30(40):5893-900. DOI: 10.1016/j.vaccine.2012.04.109. View

Padte N, Li X, Tsuji M, Vasan S . Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin Immunol. 2010; 140(2):142-51. PMC: 4449275. DOI: 10.1016/j.clim.2010.11.009. View

Sakabe S, Ozawa M, Takano R, Iwastuki-Horimoto K, Kawaoka Y . Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice. Virus Res. 2011; 158(1-2):124-9. PMC: 3103651. DOI: 10.1016/j.virusres.2011.03.022. View

Li X, Fujio M, Imamura M, Wu D, Vasan S, Wong C . Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A. 2010; 107(29):13010-5. PMC: 2919905. DOI: 10.1073/pnas.1006662107. View

Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S . Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis. 2007; 196(9):1313-20. PMC: 7110255. DOI: 10.1086/521304. View

Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S . Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol. 2005; 79(5):2910-9. PMC: 548446. DOI: 10.1128/JVI.79.5.2910-2919.2005. View

Feng H, Nakajima N, Wu L, Yamashita M, Lopes T, Tsuji M . A Glycolipid Adjuvant, 7DW8-5, Enhances the Protective Immune Response to the Current Split Influenza Vaccine in Mice. Front Microbiol. 2019; 10:2157. PMC: 6759631. DOI: 10.3389/fmicb.2019.02157. View

Pifferi C, Fuentes R, Fernandez-Tejada A . Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action. Nat Rev Chem. 2021; 5(3):197-216. PMC: 7829660. DOI: 10.1038/s41570-020-00244-3. View

Carroll E, Jin L, Mori A, Munoz-Wolf N, Oleszycka E, Moran H . The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons. Immunity. 2016; 44(3):597-608. PMC: 4852885. DOI: 10.1016/j.immuni.2016.02.004. View

10.

Kim S, Jang Y . The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants. Clin Exp Vaccine Res. 2017; 6(1):15-21. PMC: 5292352. DOI: 10.7774/cevr.2017.6.1.15. View

11.

Rajao D, Perez D . Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture. Front Microbiol. 2018; 9:123. PMC: 5808216. DOI: 10.3389/fmicb.2018.00123. View

12.

Youn H, Ko S, Lee K, Ko H, Lee Y, Fujihashi K . A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine. 2007; 25(28):5189-98. DOI: 10.1016/j.vaccine.2007.04.081. View

13.

Hjertner B, Bengtsson T, Morein B, Paulie S, Fossum C . A novel adjuvant G3 induces both Th1 and Th2 related immune responses in mice after immunization with a trivalent inactivated split-virion influenza vaccine. Vaccine. 2018; 36(23):3340-3344. DOI: 10.1016/j.vaccine.2018.04.054. View

14.

Houser K, Subbarao K . Influenza vaccines: challenges and solutions. Cell Host Microbe. 2015; 17(3):295-300. PMC: 4362519. DOI: 10.1016/j.chom.2015.02.012. View

15.

Kusakabe T, Ozasa K, Kobari S, Momota M, Kishishita N, Kobiyama K . Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection. Vaccine. 2016; 34(27):3191-3198. DOI: 10.1016/j.vaccine.2016.04.001. View

16.

Sano K, Ainai A, Suzuki T, Hasegawa H . Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics. Expert Rev Vaccines. 2018; 17(8):687-696. DOI: 10.1080/14760584.2018.1507743. View

17.

Uraki R, Das S, Hatta M, Kiso M, Iwatsuki-Horimoto K, Ozawa M . Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine. Vaccine. 2014; 32(41):5295-300. PMC: 6312188. DOI: 10.1016/j.vaccine.2014.07.079. View

18.

Hovden A, Cox R, Haaheim L . Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand J Immunol. 2005; 62(1):36-44. DOI: 10.1111/j.1365-3083.2005.01633.x. View

19.

Woodrow K, Bennett K, Lo D . Mucosal vaccine design and delivery. Annu Rev Biomed Eng. 2012; 14:17-46. DOI: 10.1146/annurev-bioeng-071811-150054. View

20.

Courtney A, Nehete P, Nehete B, Thapa P, Zhou D, Sastry K . Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine. 2009; 27(25-26):3335-41. PMC: 5798449. DOI: 10.1016/j.vaccine.2009.01.083. View